Drug Search Results
More Filters [+]

HRO-761

Alternative Names: HRO-761, HRO 761, HRO761
Latest Update: 2024-09-19
Latest Update Note: Clinical Trial Update

Product Description

Novartis is developing HRO761, an oral drug that acts on a protein called Werner (WRN), which may contribute to cancer growth. By acting on WRN, HRO761 may be able to stop the growth of the cancer. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05838768)

Mechanisms of Action: WRN Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for HRO-761

Countries in Clinic: Belgium, China, France, Germany, Israel, Italy, Japan, Korea, Norway, Singapore, Spain, Sweden, Taiwan, United Kingdom, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: Colorectal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CHRO761A12101

P1

Recruiting

Colorectal Cancer

2030-01-30

jRCT2031230088

P1

Recruiting

Colorectal Cancer

2027-02-28

Recent News Events

Date

Type

Title